Rheonova a particip\u00e9 au Lung Invitro Event 2022 au Hyatt Regency \u00e0 Nice. <\/p>\n\n\n\n
LIVe2022<\/strong>\u00a0entend bien devenir\u00a0une plateforme d’\u00e9change unique<\/strong> pour les scientifiques interess\u00e9s par la recherches dans le domaine respiratoire avec des intervenants du monde acad\u00e9mique, pharma, biotech, chimique, des dispositifs m\u00e9dicaux, CROs et agences r\u00e9glementaires. Ce rassemblement se focalisera sur les mod\u00e8les pulmonaires in vitro<\/em> pr\u00e9dictives <\/strong>con\u00e7u pour des tests d’efficacit\u00e9 et de toxicit\u00e9 ainsi que la recherche fondamentale. Il vise \u00e0 pr\u00e9senter l’\u00e9tat de l’art des mod\u00e8les pulmonaires in vitro<\/em> et \u00e0 planifier la voie de son d\u00e9veloppement et de son utilisation futurs.<\/p>\n\n\n\n Rheonova a pr\u00e9sent\u00e9 un de ces projets de recherche intitul\u00e9 : \u00ab\u00a0Rheological assessment of model mucus produced by Air-Liquid Interface epithelial cells.\u00a0\u00bb<\/p>\n\n\n\n Abstract<\/p>\n\n\n\n Mucus rheology is recognised as a key driver of bronchial obstruction in muco-obstructive diseases. However, the understanding of mucus transport mechanisms, as well as the development and characterisation of decongesting therapies, require model systems that are representative of the bronchial mucus, both biochemically and rheologically. Air-Liquid Interface (ALI) cultured epithelial cells produce mucus, with phenotype representative of several conditions (healthy, asthma, COPD, cystic fibrosis) and several depths within the airway tree (nose, bronchi). This mucus is collected for rheological analysis, and compared with sputum samples collected from patients.<\/p>\n\n\n\n <\/p>\n","protected":false},"excerpt":{"rendered":"